![\"Zixing](\"https:\/\/blogs.manchester.ac.uk\/bsrbr-blog\/wp-content\/uploads\/sites\/440\/2024\/07\/photo_Zixing-300x288.jpg\")
where I recently published an analysis on how patients with RA using Janus kinase (JAK) inhibitors are affected by the European Medicines Agency (EMA) advisory change.<\/p>\n[et_pb_section bb_built=”1″ admin_label=”section” fullwidth=”on” next_background_color=”#000000″ global_module=”322″][et_pb_fullwidth_menu global_parent=”322″ _builder_version=”3.0.106″ menu_id=”7″ submenu_direction=”downwards” fullwidth_menu=”off” background_layout=”dark” module_class=”main-navigation” \/][\/et_pb_section][et_pb_section bb_built=”1″ fullwidth=”off” specialty=”on” prev_background_color=”#000000″ next_background_color=”#1d1d1d”][et_pb_column type=”2_3″ specialty_columns=”2″][et_pb_row_inner locked=”off”][et_pb_column_inner type=”4_4″ saved_specialty_column_type=”2_3″][et_pb_post_title _builder_version=”3.17.6″ featured_placement=”above” locked=”on” parent_locked=”off” date_format=”j M Y” \/][et_pb_text _builder_version=”3.17.6″ background_layout=”light” parent_locked=”off”]<\/p>\n
Read about some of the recent research from BSRBR-RA looking at JAK inhibitors.<\/p>\n
Hello, my name is Zixing Tian, I am an epidemiologist with a research focus on rheumatoid arthritis (RA). I work on the BSRBR-RA study, where I recently published an analysis on how patients with RA using Janus kinase (JAK) inhibitors are affected by the European Medicines Agency (EMA) advisory change.<\/p>\n
JAK inhibitors are the newest type (or class) of advanced RA treatment and have been available since 2017. Four JAK inhibitors have been approved by the EMA which evaluates and supervises medicine use in the European Union. These include Jyseleca, Olumiant, Xeljanz and Rinvoq.<\/p>\n
In 2023, the EMA limited the use of JAK inhibitors to certain high-risk patients unless no other suitable treatments are available, due to evidence suggesting that JAK inhibitors increase the risk of cardiovascular disease or cancer compared to TNF inhibitors (another advanced RA treatment). This advisory change was also adopted by the UK Medicines and Healthcare Products Regulatory Agency (MHRA). The four at-risk patient groups include:<\/p>\n
I wanted to investigate how many RA patients using JAK inhibitors in the UK do not fit the new safety guidelines from the EMA. This will help us understand how these changes might affect JAK inhibitor prescriptions now and in the future.<\/p>\n
I used the BSRBR-RA data, which is a national cohort study, established in 2001, of over 30,000 patients with RA on biological therapies (otherwise known as Biologic Disease Modifying Anti-Rheumatic Drugs or bDMARDs) and JAK inhibitors. This cohort study has been recruiting RA patients using JAK inhibitors since 2017. The four other classes of targeted therapies (bDMARDs) have been available for much longer than the JAK inhibitors and the BSRBR-RA has captured extensive long-term data showing the safety and effectiveness of the bDMARDs.<\/p>\n
We found that among 1,341 RA patients who had started the JAK inhibitors before EMA advisory change, 80% (1,075 patients) met at least one EMA risk criterion. Of these high-risk patients:<\/p>\n
![\"A](\"https:\/\/blogs.manchester.ac.uk\/bsrbr-blog\/wp-content\/uploads\/sites\/440\/2024\/07\/blogchart.png\")
Figure Number of prior distinct of bDMARDs in patients who had \u22651 EMA risk criterion (N=1075)<\/p><\/div>\n
This is just the start of the JAK inhibitor story in the BSRBR-RA data and I would like to go on to look at the following once more data has been collected:\u00a0<\/span>\u00a0<\/span><\/p>\n [\/et_pb_text][et_pb_post_nav _builder_version=”3.0.106″ in_same_term=”off” show_prev=”on” show_next=”on” prev_text=”Previous” next_text=”Next” locked=”on” parent_locked=”off” \/][et_pb_comments _builder_version=”3.0.106″ show_avatar=”on” show_reply=”on” show_count=”on” background_layout=”light” header_font_size_tablet=”51″ header_line_height_tablet=”2″ custom_button=”on” button_icon_placement=”right” button_text_color=”#ffffff” button_use_icon=”off” locked=”on” parent_locked=”off” button_text_size__hover_enabled=”off” button_text_size__hover=”null” button_one_text_size__hover_enabled=”off” button_one_text_size__hover=”null” button_two_text_size__hover_enabled=”off” button_two_text_size__hover=”null” button_text_color__hover_enabled=”off” button_text_color__hover=”null” button_one_text_color__hover_enabled=”off” button_one_text_color__hover=”null” button_two_text_color__hover_enabled=”off” button_two_text_color__hover=”null” button_border_width__hover_enabled=”off” button_border_width__hover=”null” button_one_border_width__hover_enabled=”off” button_one_border_width__hover=”null” button_two_border_width__hover_enabled=”off” button_two_border_width__hover=”null” button_border_color__hover_enabled=”off” button_border_color__hover=”null” button_one_border_color__hover_enabled=”off” button_one_border_color__hover=”null” button_two_border_color__hover_enabled=”off” button_two_border_color__hover=”null” button_border_radius__hover_enabled=”off” button_border_radius__hover=”null” button_one_border_radius__hover_enabled=”off” button_one_border_radius__hover=”null” button_two_border_radius__hover_enabled=”off” button_two_border_radius__hover=”null” button_letter_spacing__hover_enabled=”off” button_letter_spacing__hover=”null” button_one_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover=”null” button_two_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover=”null” button_bg_color__hover_enabled=”off” button_bg_color__hover=”null” button_one_bg_color__hover_enabled=”off” button_one_bg_color__hover=”null” button_two_bg_color__hover_enabled=”off” button_two_bg_color__hover=”null” \/][et_pb_text admin_label=”Related posts” _builder_version=”3.0.106″ background_layout=”light” locked=”on” parent_locked=”off”]<\/p>\n [\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][\/et_pb_column][et_pb_column type=”1_3″][et_pb_sidebar _builder_version=”3.0.106″ area=”sidebar-1″ orientation=”left” show_border=”off” background_layout=”light” locked=”on” \/][\/et_pb_column][\/et_pb_section][et_pb_section bb_built=”1″ admin_label=”Connect Title” custom_padding=”0px||0px|” _builder_version=”3.0.90″ background_color=”#1d1d1d” module_class=”footer-section” prev_background_color=”#ffffff” global_module=”380″][et_pb_row admin_label=”row” global_parent=”380″ locked=”off” allow_player_pause=”off” parallax=”off” parallax_method=”on” parallax_1=”off” parallax_method_1=”off” parallax_2=”off” parallax_method_2=”off” parallax_3=”off” parallax_method_3=”off” make_fullwidth=”off” use_custom_width=”off” width_unit=”on” use_custom_gutter=”off” make_equal=”off” module_id=”footer-row” _builder_version=”3.0.89″][et_pb_column type=”1_3″][et_pb_text admin_label=”Contact Us Title” global_parent=”380″ background_layout=”dark” text_text_color=”#ffffff” parent_locked=”off” background_position=”top_left” background_repeat=”repeat” background_size=”initial”]<\/p>\n [\/et_pb_text][et_pb_text admin_label=”Contact Us” global_parent=”380″ text_text_color=”#aaaaaa” parent_locked=”off” background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid” module_class=”contact-us” background_position=”top_left” background_repeat=”repeat” background_size=”initial”]<\/p>\n +44 (0) 161 306 6000<\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″][et_pb_text admin_label=”Find Us Title” global_parent=”380″ background_layout=”dark” text_text_color=”#ffffff” parent_locked=”off” background_position=”top_left” background_repeat=”repeat” background_size=”initial”]<\/p>\n [\/et_pb_text][et_pb_text admin_label=”Address” global_parent=”380″ background_layout=”dark” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid” module_id=”address” parent_locked=”off” background_position=”top_left” background_repeat=”repeat” background_size=”initial”]<\/p>\n The University of Manchester [\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″][et_pb_text admin_label=”Connect Title” global_parent=”380″ background_layout=”dark” text_text_color=”#ffffff” parent_locked=”off” background_position=”top_left” background_repeat=”repeat” background_size=”initial”]<\/p>\n [\/et_pb_text][et_pb_code admin_label=”Social Media” global_parent=”380″ parent_locked=”off” _builder_version=”3.17.6″]<\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/ul>\n [\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" Read about some of the recent research from BSRBR-RA looking at JAK inhibitors. Bit of background about you Hello, my name is Zixing Tian, I am an epidemiologist with a research focus on rheumatoid arthritis (RA). I work on the BSRBR-RA study, where I recently published an analysis on how patients with RA using Janus […]<\/p>\n","protected":false},"author":7109,"featured_media":1486,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_exactmetrics_skip_tracking":false,"footnotes":""},"categories":[16,9,10],"tags":[],"class_list":["post-1609","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biologic-therapy","category-research","category-study-results"],"_links":{"self":[{"href":"https:\/\/blogs.manchester.ac.uk\/bsrbr-blog\/wp-json\/wp\/v2\/posts\/1609","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.manchester.ac.uk\/bsrbr-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.manchester.ac.uk\/bsrbr-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.manchester.ac.uk\/bsrbr-blog\/wp-json\/wp\/v2\/users\/7109"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.manchester.ac.uk\/bsrbr-blog\/wp-json\/wp\/v2\/comments?post=1609"}],"version-history":[{"count":2,"href":"https:\/\/blogs.manchester.ac.uk\/bsrbr-blog\/wp-json\/wp\/v2\/posts\/1609\/revisions"}],"predecessor-version":[{"id":1614,"href":"https:\/\/blogs.manchester.ac.uk\/bsrbr-blog\/wp-json\/wp\/v2\/posts\/1609\/revisions\/1614"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blogs.manchester.ac.uk\/bsrbr-blog\/wp-json\/wp\/v2\/media\/1486"}],"wp:attachment":[{"href":"https:\/\/blogs.manchester.ac.uk\/bsrbr-blog\/wp-json\/wp\/v2\/media?parent=1609"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.manchester.ac.uk\/bsrbr-blog\/wp-json\/wp\/v2\/categories?post=1609"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.manchester.ac.uk\/bsrbr-blog\/wp-json\/wp\/v2\/tags?post=1609"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
Related<\/h1>\n
Related posts:<\/h3>
<\/div><\/div><\/div>Celebrate your registers! Collaboration: Successful collaboration with patient groups<\/h2><\/div><\/div><\/a>
<\/div>Celebrate your registers! Development: Encouraging researchers<\/h2><\/div><\/div><\/a>
<\/div>Celebrate your registers! Influence: Influencing clinical guidelines<\/h2><\/div><\/div><\/a><\/div>
<\/div><\/div><\/div>\nContact Us<\/h4>\n
Find Us<\/h4>\n
Oxford Rd
Manchester
M13 9PL
UK<\/a><\/p>\nConnect With Us<\/h4>\n
<\/p>\n
![\"Facebook](\"\/\/assets.manchester.ac.uk\/phase1\/templates\/images\/icon-facebook-50.png\"){kind=icon}
<\/a><\/li>\n![\"Twitter](\"\/\/assets.manchester.ac.uk\/phase1\/templates\/images\/icon-twitter-50.png\"){kind=icon}
<\/a><\/li>\n![\"YouTube](\"\/\/assets.manchester.ac.uk\/phase1\/templates\/images\/icon-youtube-50.png\"){kind=icon}
<\/a><\/li>\n![\"Instagram](\"\/\/assets.manchester.ac.uk\/phase1\/templates\/images\/icon-instagram-50.svg\"){kind=icon}
<\/a><\/li>\n